Literature DB >> 6823104

Experimental evaluation of secondary blood cardioplegia.

J H Rousou, R M Engelman, W A Dobbs.   

Abstract

Reperfusion damage after ischemia may be evidenced by myocardial cell edema, intracellular calcium accumulation, and limited utilization of oxygen. The need for cardioplegic arrest during initial reperfusion to allow oxygen to be used for reversing ischemic damage rather than for electromechanical activity has been propounded by some researchers. Reports of greater postischemic compliance and performance, low postischemic edema, and greater oxygen uptake at a perfusion pressure of 50 mm Hg or lower have been cited. The present study was conducted on 24 pigs having 2-hr cardioplegic arrest, which of 12 underwent normal reperfusion and 12 experienced secondary cardioplegia followed by normal reperfusion. The results showed that in spite of improved high-energy phosphate preservation, the secondary cardioplegia group had higher myocardial edema, less coronary flow, and poorer contractility and compliance at the end of 1 hr of reperfusion. Because of these findings and contradictory results reported by other groups, caution is urged in the clinical extrapolation of the results of such studies pending further investigations.

Entities:  

Mesh:

Year:  1983        PMID: 6823104     DOI: 10.1016/0022-4804(83)90048-3

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  2 in total

1.  Prevention of postischemic reperfusion injury: the improvement of myocardial tissue blood flow after ischemia by terminal nicorandil-Mg cardioplegia.

Authors:  H Orita; M Fukasawa; S Hirooka; T Minowa; H Uchino; M Washio
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

2.  Accelerated myocardial metabolic and functional recovery with terminal nicorandil-Mg cardioplegia in heart transplantation.

Authors:  H Orita; T Shimanuki; M Fukasawa; H Abe; S Kuraoka; S Hirooka; M Washio
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.